ATE498408T1 - Gnrh-agonistische kombinationsmittel - Google Patents
Gnrh-agonistische kombinationsmittelInfo
- Publication number
- ATE498408T1 ATE498408T1 AT02758814T AT02758814T ATE498408T1 AT E498408 T1 ATE498408 T1 AT E498408T1 AT 02758814 T AT02758814 T AT 02758814T AT 02758814 T AT02758814 T AT 02758814T AT E498408 T1 ATE498408 T1 AT E498408T1
- Authority
- AT
- Austria
- Prior art keywords
- drugs
- gnrh
- gnrh agonist
- qol
- preventive
- Prior art date
Links
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 title 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 title 1
- 230000001270 agonistic effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 4
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 abstract 3
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 3
- 239000000556 agonist Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000003449 preventive effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 1
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 abstract 1
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 abstract 1
- 229940127394 Sex Hormone Synthesis Inhibitors Drugs 0.000 abstract 1
- 230000004097 bone metabolism Effects 0.000 abstract 1
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000849 selective androgen receptor modulator Substances 0.000 abstract 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 abstract 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001244616 | 2001-08-10 | ||
| PCT/JP2002/008130 WO2003015820A1 (en) | 2001-08-10 | 2002-08-08 | GnRH AGONIST COMBINATION DRUGS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE498408T1 true ATE498408T1 (de) | 2011-03-15 |
Family
ID=19074519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02758814T ATE498408T1 (de) | 2001-08-10 | 2002-08-08 | Gnrh-agonistische kombinationsmittel |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20050215528A1 (de) |
| EP (1) | EP1424080B1 (de) |
| JP (1) | JP2003137814A (de) |
| AT (1) | ATE498408T1 (de) |
| CA (1) | CA2458452C (de) |
| DE (1) | DE60239207D1 (de) |
| WO (1) | WO2003015820A1 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE498408T1 (de) * | 2001-08-10 | 2011-03-15 | Takeda Pharmaceutical | Gnrh-agonistische kombinationsmittel |
| US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
| CA2490351C (en) | 2002-06-25 | 2011-11-01 | Takeda Pharmaceutical Company Limited | Process for producing sustained-release composition |
| EP1553074B1 (de) | 2002-08-12 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Kondensiertes benzolderivat und verwendung |
| GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0307777D0 (en) * | 2003-04-04 | 2003-05-07 | Medical Res Council | Conjugate compounds |
| WO2004100991A1 (en) * | 2003-05-15 | 2004-11-25 | Universite Catholique De Louvain | Use of endothelin-1 antagonists for improving cancer therapy |
| JP2004344035A (ja) * | 2003-05-21 | 2004-12-09 | Kureha Chem Ind Co Ltd | 担子菌の乾燥方法 |
| GB0320806D0 (en) * | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Therapeutic treatment |
| WO2005072746A1 (ja) * | 2004-01-30 | 2005-08-11 | Astellas Pharma Inc. | P2x受容体阻害剤 |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
| US8758821B2 (en) | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
| MXPA06012758A (es) | 2004-05-04 | 2007-01-16 | Hormos Medical Ltd | Novedosas formulaciones orales de ospemifeno. |
| US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
| CN102976973B (zh) * | 2004-06-07 | 2015-10-21 | 田纳西大学研究基金会 | 选择性雄激素受体调节剂及其使用方法 |
| US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
| US20080171736A1 (en) * | 2004-12-23 | 2008-07-17 | Gregory Christopher W | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists |
| US20100069387A1 (en) * | 2005-09-07 | 2010-03-18 | Palmer Stephen S | IKK Inhibitors for the Treatment of Endometriosis |
| BRPI0707671A2 (pt) * | 2006-02-09 | 2011-05-10 | Daiichi Sankyo Co Ltd | composiÇço farmacÊutica anti-cÂncer |
| WO2008099060A2 (en) * | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
| ES2590262T3 (es) * | 2007-02-14 | 2016-11-21 | Hormos Medical Ltd. | Método para la preparación de derivados de trifenilbuteno con valor terapéutico |
| US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
| EP2187934A1 (de) * | 2007-09-11 | 2010-05-26 | Mondobiotech Laboratories AG | Verwendung von fertirelin und delta-endorphin als therapeutische mittel |
| JP5937297B2 (ja) * | 2010-03-01 | 2016-06-22 | キヤノンアネルバ株式会社 | 金属窒化膜、該金属窒化膜を用いた半導体装置、および半導体装置の製造方法 |
| KR20170127044A (ko) * | 2010-06-16 | 2017-11-20 | 앙도르쉐르슈 인코포레이티드 | 에스트로겐-관련 질병의 치료 또는 예방 방법 |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| KR102122941B1 (ko) | 2012-07-13 | 2020-06-15 | 지티엑스, 인코포레이티드 | 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법 |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| WO2014060639A1 (en) | 2012-10-19 | 2014-04-24 | Fermion Oy | A process for the preparation of ospemifene |
| WO2019222856A1 (en) | 2018-05-24 | 2019-11-28 | Nureva Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| AU2019275409B2 (en) | 2018-05-24 | 2024-08-15 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| JP2021524841A (ja) | 2018-05-24 | 2021-09-16 | セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー | 高分子薬剤化合物の持続放出用の埋め込み型デバイス |
| EP4329734A4 (de) | 2021-04-26 | 2025-04-02 | Celanese EVA Performance Polymers LLC | Implantierbare vorrichtung zur verzögerten freisetzung einer makromolekularen arzneimittelverbindung |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2438350C3 (de) * | 1974-08-09 | 1979-06-13 | Hoechst Ag, 6000 Frankfurt | Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen |
| FR2465486A1 (fr) * | 1979-09-21 | 1981-03-27 | Roussel Uclaf | Nouvelle application utilisant la lh-rh ou des agonistes |
| DE3586053D1 (de) * | 1984-08-02 | 1992-06-17 | Labrie | Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs. |
| DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
| CA2250908C (en) * | 1996-04-30 | 2012-03-13 | Takeda Chemical Industries, Ltd. | Combined use of gnrh agonist and antagonist |
| US20020019346A1 (en) * | 1997-05-21 | 2002-02-14 | Children's Medical Center Corporation | Treatment of prostate cancer by inhibiting lyn tyrosine kinase |
| DK1011648T4 (da) * | 1997-08-15 | 2005-10-24 | Cephalon Inc | Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer |
| KR100577877B1 (ko) * | 1998-01-16 | 2006-05-09 | 다케다 야쿠힌 고교 가부시키가이샤 | 서방성 조성물, 그것의 제조방법 및 용도 |
| US6573289B1 (en) * | 1998-04-23 | 2003-06-03 | Takeda Chemical Industries, Ltd. | Naphthalene derivatives, their production and use |
| DE19833786A1 (de) * | 1998-07-18 | 2000-01-20 | Schering Ag | Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| ID28791A (id) * | 1998-08-07 | 2001-07-05 | Endorech Inc | PENGHAMBATAN DEHIDROGENASE HIDROKSISTEROID 3α TIPE 3 |
| US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| CA2388508A1 (en) * | 1999-10-22 | 2001-05-03 | Takeda Chemical Industries, Ltd. | 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof |
| JP4520012B2 (ja) * | 1999-10-22 | 2010-08-04 | 武田薬品工業株式会社 | １−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類 |
| GB0008368D0 (en) * | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
| PE20011178A1 (es) * | 2000-04-07 | 2001-11-19 | Takeda Chemical Industries Ltd | Compuestos heterociclicos y su produccion |
| AU2001269439A1 (en) * | 2000-07-05 | 2002-01-14 | Takeda Chemical Industries Ltd. | Medicinal preparations for treating sex hormone-dependent diseases |
| JP4121268B2 (ja) * | 2000-11-20 | 2008-07-23 | 武田薬品工業株式会社 | イミダゾール誘導体、その製造法および用途 |
| JP4160295B2 (ja) * | 2000-12-08 | 2008-10-01 | 武田薬品工業株式会社 | ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途 |
| JP2002241268A (ja) * | 2000-12-11 | 2002-08-28 | Takeda Chem Ind Ltd | 水溶解性が改善された医薬組成物 |
| EP1382350A4 (de) * | 2001-04-25 | 2006-01-04 | Takeda Pharmaceutical | Mittel zur prophylaxe vor postoperativem wiederauftreten von prämenopausalem brustkrebs |
| US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| ATE498408T1 (de) * | 2001-08-10 | 2011-03-15 | Takeda Pharmaceutical | Gnrh-agonistische kombinationsmittel |
| WO2003041739A1 (fr) * | 2001-11-13 | 2003-05-22 | Takeda Chemical Industries, Ltd. | Agents anticancer |
-
2002
- 2002-08-08 AT AT02758814T patent/ATE498408T1/de not_active IP Right Cessation
- 2002-08-08 EP EP02758814A patent/EP1424080B1/de not_active Expired - Lifetime
- 2002-08-08 DE DE60239207T patent/DE60239207D1/de not_active Expired - Lifetime
- 2002-08-08 JP JP2002231922A patent/JP2003137814A/ja active Pending
- 2002-08-08 US US10/486,095 patent/US20050215528A1/en not_active Abandoned
- 2002-08-08 WO PCT/JP2002/008130 patent/WO2003015820A1/ja not_active Ceased
- 2002-08-08 CA CA2458452A patent/CA2458452C/en not_active Expired - Fee Related
-
2007
- 2007-03-27 US US11/727,549 patent/US20070179097A1/en not_active Abandoned
-
2010
- 2010-05-07 US US12/662,866 patent/US20100286063A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003015820A1 (en) | 2003-02-27 |
| EP1424080B1 (de) | 2011-02-16 |
| CA2458452A1 (en) | 2003-02-27 |
| US20050215528A1 (en) | 2005-09-29 |
| EP1424080A1 (de) | 2004-06-02 |
| EP1424080A4 (de) | 2004-09-01 |
| CA2458452C (en) | 2011-04-19 |
| JP2003137814A (ja) | 2003-05-14 |
| US20100286063A1 (en) | 2010-11-11 |
| DE60239207D1 (de) | 2011-03-31 |
| US20070179097A1 (en) | 2007-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE498408T1 (de) | Gnrh-agonistische kombinationsmittel | |
| Dorai et al. | Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein | |
| DE602005013490D1 (de) | Missbrauchsichere transdermale abgabevorrichtung für opioide, enthaltend opioidantagonist in form von mikrokügelchen | |
| ATE556060T1 (de) | Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| AP2004002982A0 (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain. | |
| DK1379224T3 (da) | Guanylat-cyclase receptor-agonister til behandling af vævsinflammation og carciogenese | |
| MY149856A (en) | Therapeutic agent for mesothelioma | |
| ATE469897T1 (de) | Indazolcarbonsäureamidverbindungen | |
| MA32397B1 (fr) | Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité | |
| GEP20063741B (en) | Nonaryl-Heterocyclic NMDA/NR2B Antagonists | |
| ECSP034772A (es) | Antagonistas de mch y su uso en el tratamiento de obesidad | |
| MX2009003469A (es) | Uso de farmacos que inducen hipotermia para el tratamiento de isquemia. | |
| TW200730168A (en) | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | |
| BRPI0409910A (pt) | métodos para o tratamento de doenças relacionadas com interleucina-6 | |
| BR0010138A (pt) | Moduladores de receptores de glucocorticóides | |
| EA200800618A1 (ru) | Комбинация снотворного агента длительного действия и снотворного агента короткого действия | |
| SI1627639T1 (sl) | Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj | |
| EA200501019A1 (ru) | Противораковое лекарственное средство, фармацевтическая композиция и способ ингибирования размера опухоли (варианты) на его основе | |
| TW200531679A (en) | Methods of modulating cytokine activity; related reagents | |
| IL162862A0 (en) | Short-acting sedative hypnotic agents for anesthesia and sedation | |
| DK1781277T3 (da) | Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol | |
| MXPA05012705A (es) | Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral. | |
| MXPA05013478A (es) | Combinaciones terapeuticas. | |
| MXPA05009135A (es) | Formulaciones liquidas de las proteinas de union del factor necrosis del tumor. | |
| EA200801369A1 (ru) | Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |